MYOUNGHEE KANG

Dr. MYOUNGHEE KANG

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Journal of hospice and palliative care
Verified
Journal Article
Open access
PDF file
SGSe-Il Go
Se-Il Go
MKMYOUNGHEE KANG
MYOUNGHEE KANG
HKHoon-Gu Kim
Hoon-Gu Kim
Se-Il Go, M.D.1, Myoung Hee Kang, M.D.1 and Hoon-Gu Kim, M.D., Ph.D.. J Hosp Palliat Care 2025;28:10-7. https://doi.org/10.14475/jhpc.2025.28.1.10

Verified
Journal Article
Open access
PDF file
MKMYOUNGHEE KANG
MYOUNGHEE KANG
SGSe-Il Go
Se-Il Go
WLWon Sup Lee
Won Sup Lee
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly desmoplastic and immunosuppressive tumor microenvironment (TME) that limits immune-cell infiltration, impairs antigen presentation, and promotes tumor-supportive myeloid responses. CD40 agonism offers a distinct immunotherapeutic strategy by activating macrophages and antigen-presenting cells (APCs), enhancing antigen presentation, and promoting innate and adaptive antitumor immunity. Preclinical studies have demonstrated macrophage-dependent tumor regression and stromal remodeling, while combination with chemotherapy can enhance antigen release and subsequent immune priming. Clinical studies of CD40 agonists, including sotigalimab, mitazalimab, and selicrelumab, have demonstrated immune and TME remodeling, but consistent survival benefit has not been established in unselected patients. Differences in treatment context, chemotherapy backbone, treatment sequence, and antibody architecture may contribute to variable clinical outcomes. Emerging evidence indicates that limited therapeutic activity may reflect multiple factors, including APC deficiency, persistent immunosuppression, inadequate effector responses, stromal and spatial immune exclusion, and pharmacologic limitations related to Fcγ receptor engagement and systemic toxicity. Future development should therefore emphasize biomarker-guided patient selection, rational treatment sequencing, spatially controlled CD40 activation, and mechanistically matched combination strategies. Integration of immune, molecular, and pharmacodynamic biomarkers, together with next-generation CD40 agonists, may help translate CD40-mediated immune remodeling into more durable clinical benefit in PDAC.